Hexagon Nutrition Q4FY26 Investor Presentation Released; Earnings Call Scheduled
Hexagon Nutrition Limited released its Q4FY26 investor presentation and held an earnings call on July 17, 2026. FY26 revenue reached ₹382.6 crore, with EBITDA at ₹52.9 crore and PAT at ₹37.9 crore. The company highlighted a 13.4% revenue CAGR (FY24-26) and a 76.2% PAT CAGR (FY24-26). ROCE improved to 20.82% with a near debt-free status (D/E 0.13x).
The detailed investor presentation and strong financial performance reported are significant for investors and stakeholders, providing insights into the company's strategy and future prospects.
The company's financial performance shows strong growth in revenue, EBITDA, and PAT, along with improved return ratios and a healthy balance sheet, indicating a positive outlook.
Hexagon Nutrition Limited has released its investor presentation for the fourth quarter and financial year ended March 31, 2026. This follows the company's intimation of an earnings call scheduled for Friday, July 17, 2026, at 04:00 p.m., to discuss its financial performance.
The presentation, which is also available on the company's website, provides details on the company's overview, manufacturing and R&D capabilities, product portfolio, industry landscape, financial performance, growth strategy, and management.
Key highlights from the presentation include a FY26 Revenue of ₹3,826 million (₹382.6 crore) with a 13.4% CAGR (FY24-FY26), FY26 EBITDA of ₹529 million (₹52.9 crore) at a margin of 13.82%, and FY26 PAT of ₹379 million (₹37.9 crore) with a significant PAT CAGR of 76.2% (FY24-26). The company also reported an improved ROCE of 20.82% and a near debt-free status with a D/E ratio of 0.13x. The presentation elaborates on the company's integrated business model, diverse product portfolio across B2C (Clinical and Wellness Nutrition) and B2B2C (Premix) segments, and its extensive manufacturing footprint across four plants in three countries. It also outlines the company's growth strategy focusing on new product categories, strengthening domestic presence, expanding global exports, premium B2B2C premix growth, and manufacturing efficiency with a target EBITDA margin of over 15% in the medium term.
What to do with a filing like this
Hexagon Nutrition Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Hexagon Nutrition Limited. Read the original for the full detail.